

Attorney's Docket No. 018995-452

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Nishizumi NISHIMUTA et al

Application No.: 10/046,575

Filed: January 16, 2002

For: EXTERNAL PREPARATION FOR SKIN DISEASES CONTAINING NITROIMIDAZOLE

Corontal Variables of Confirmation No. 4939

SECOND INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

[X]	No additional fee for submission of an IDS is required.					
[]	The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.					
[]	A certification under 37 C.F.R. § 1.97(e) is also enclosed.					
[]	A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set fort in 37 C.F.R. § 1.17(p) are also enclosed.					
[]	Charge \$ to Deposit Account No. 02-4800 for the fee due.					
f 1	A check in the amount of \$ is enclosed for the fee due.					

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: November 14, 2002

Susan M. Dadio Registration No. 40,373



IN THE UNITED STATES PATEN	T AND TRADEMARK OFFICE
In re Patent Application of) En la Ch
Nishizumi NISHIMUTA et al.) Group Art Unit: 1614
Application No.: 10/046,575	Examiner: Unassigned Confirmation No.: 4939
Filed: January 16, 2002) Confirmation No.: 4939
For: EXTERNAL PREPARATION FOR SKIN DISEASES CONTAINING NITROIMIDAZOLE	,))

SECOND INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

OTHER NON-PATENT DOCUMENTS

- 1. KOSTAKIS et al., "The Immunosuppressive Action of Metronidazole," *IRCS Medical Science*, 1977, p. 142, Vol. 5.
 - 2. Pharmacy, 1996, pp. 1137-1141, Vol. 47, No. 8.

This Information Disclosure Statement contains information which is not in the English language. In accordance with M.P.E.P. § 609 A(3) a concise explanation of relevance for the non-English language information is as follows:

Second Information Disclosure Statement Application Serial No. 10/046,575 Attorney's Docket No. 018995-452 Page 2

The *Pharmacy* article (47(8):1137-1141 (1996)) discloses that a pharmaceutical composition for external application containing cyclosporin (CsA) and tacrolimus (FK506) which are known to have immune suppressive effects at the organ transplantation are useful as a therapeutic agent for atopic dermatitis (Fig. 1 on page 1139).

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore under 37 C.F.R. § 1.97(b) no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,


BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: November 14, 2002

Susan M. Dadio

Registration No. 40,373

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620



SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT No.	APPLICATION NO.							
018995-452	10/046,575							
APPLICANT								
Nishizumi NISHIMUTA et al.								
FILING DATE	GROUP							
January 16, 2002	1614							

U.S. PATENT DOCUMENTS										
U.S. Patent Document				 						
Examiner		Kind Code	Name of Patente			Date of Public		ļ		
Initials	Number	(if known)	of Cited Document			(MM-DD-YYYY)				
	 	++				<u> </u>				
	 	++								
	ļ	 								
	 	 				1	<u></u>			
		 				Ti I	$\widetilde{\overline{U}}$			
						7 9	<u> </u>			
						竹一	<u> </u>			
	İ	<u> </u>				17 5		<u>a</u>		
						2 6	2 Y	3		
						8				
						13				
		1				8				
. Was a second of the second		FOI	REIGN PATENT DO	CUMENTS						
	Foreign Patent	t Document	<u>,</u>				T			
Examiner		Kind Code	2			ate of Publication		slation		
Initials	Number	(if known)	Country			(MM-DD-YYYY)	Yes	no		
	ļ	+ . +					 '	├──		
		+					 	├ ─		
		 					 '	 		
							<u> </u>	 		
	<u> </u>	1					'			
							<u> </u>	<u> </u>		
		NON PA	ATENT LITERATURE	E DOCUMEN	NTS					
	Include		(in CAPITAL LETTERS), 1			n appropriate), title of t	he			
Examiner		c, magazine, journa	al, serial, symposium, ca	atalog, etc.), da	ate, pag	e(s), volume-issue numb				
Initials	KOSTAKIS et al. "		publisher, city and/or corressive Action of Metror				2 Val I			
	Pharmacy, 1996, p			1108ZUIE, INCO	Weulca	/ Science, 1977, p. 144	., VOI. U	··		
	Filannacy, 1000, p	p. 1107-11-17 -	Dr. 47, 140. C.							
	 									
	†									
Examiner Signature				Date Considered						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.